SCHEMBL4015310

SCHEMBL4015310

Nc1ccc(CO)c(Cl)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.52
TSHR P16473 3/20 0.52
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
ALDH1A1 P00352 4/20 0.45
THRB P10828 2/20 0.45
ALOX15 P16050 2/20 0.45
HPGD P15428 1/20 0.45
CASP1 P29466 1/20 0.45
RECQL P46063 1/20 0.45
HSD17B10 Q99714 1/20 0.45
EPHX2 P34913 1/20 0.43
NR1H4 Q96RI1 1/20 0.43
PDE7A Q13946 1/20 0.39
HTT P42858 4/20 0.39
IDO1 P14902 3/20 0.39
GAA P10253 3/20 0.38
POLB P06746 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
ITGB2 P05107 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29362177 0.83 CA1 (0.48) CYP3A4TSHRCA1CA2ALDH1A1
SCHEMBL1625228 0.83 CA1 (0.48) CYP3A4TSHRCA1CA2ALDH1A1
SCHEMBL444686 0.82 CYP3A4 (0.52) CYP3A4TSHRCA1CA2ALDH1A1
SCHEMBL31175763 0.81 CYP3A4 (0.56) CYP3A4TSHRCA1CA2ALDH1A1
SCHEMBL352023 0.81 CYP3A4 (0.56) CYP3A4TSHRCA1CA2ALDH1A1
SCHEMBL14085077 0.79 CYP3A4 (0.54) CYP3A4TSHRCA1CA2ALDH1A1
SCHEMBL13183889 0.78 PRKCI (0.42) CYP3A4TSHRCA1CA2ALDH1A1
SCHEMBL1299722 0.77 CYP3A4 (0.52) CYP3A4TSHRCA1CA2ALDH1A1
SCHEMBL18099369 0.77 CYP3A4 (0.52) CYP3A4TSHRCA1CA2ALDH1A1
SCHEMBL8246413 0.77 CYP3A4 (0.52) CYP3A4TSHRCA1CA2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260070915-A1 SUBSTITUTED 7H-PYRROLO[2,3-D]PYRIMIDIN-2-AMINES AS SELECTIVE CDK2/4 INHIBITORS INCYTE CORP (US) 2026-03-12 US disclosed
EP-4673474-A2 ANTI-PSMA ANTIBODIES, CONJUGATES, AND METHODS OF USE Eisai R&D Management Co., Ltd. (JP) 2026-01-07 EP disclosed
WO-2024182569-A2 ANTI-PSMA ANTIBODIES, CONJUGATES, AND METHODS OF USE EISAI R&D MANAGEMENT CO., LTD. (JP) 2024-09-06 WO disclosed
WO-2024145483-A1 COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND METHODS OF MAKING AND USING THE SAME HTG MOLECULAR DIAGNOSTICS, INC. (US) 2024-07-04 WO disclosed
EP-1558567-B1 NOVEL AMIDE COMPOUNDS WITH MCH ANTAGONISTIC EFFECT AND MEDICAMENTS COMPRISING SAID COMPOUNDS BOEHRINGER INGELHEIM PHARMA (DE) 2009-06-24 EP disclosed
EP-1966222-A2 PYRAZOLOTHIAZOLE PROTEIN KINASE MODULATORS SGX Pharmaceuticals, Inc. (US) 2008-09-10 EP disclosed
US-7351719-B2 Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2008-04-01 US disclosed
US-20070173488-A1 Pyrazolothiazole Protein Kinase Modulators SGX PHARMACEUTICALS, INC. (US) 2007-07-26 US disclosed
US-20070173488-A1 Pyrazolothiazole Protein Kinase Modulators SGX PHARMACEUTICALS, INC. (US) 2007-07-26 US disclosed
US-20070173488-A1 Pyrazolothiazole Protein Kinase Modulators SGX PHARMACEUTICALS, INC. (US) 2007-07-26 US disclosed
EP-0798292-B1 ANILINE DERIVATIVES HAVING NITROGEN MONOXIDE SYNTHASE INHIBITORY ACTIVITY CHUGAI SEIYAKUKABUSHIKI KAISHA (JP) 2004-11-03 EP disclosed
US-20040152742-A1 Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-08-05 US disclosed
WO-2004039764-A1 NOVEL AMIDE COMPOUNDS WITH MCH ANTAGONISTIC EFFECT AND MEDICAMENTS COMPRISING SAID COMPOUNDS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-05-13 WO disclosed
US-6534546-B1 Guanidine- or isothioureido-N-derived anilines; brain, nervous system, and neurodegenerative disorders CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2003-03-18 US disclosed
CN-1310169-A Anils with nitric oxide synzyme inhibiting function SHUGAI SEIYAKU K K (JP) 2001-08-29 CN disclosed
CN-1172473-A Aniline derivatives having nitric oxide synthase inhibitory activity CHUGAI PHARMACEUTICAL CO LTD (JP) 1998-02-04 CN disclosed
EP-0798292-A1 ANILINE DERIVATIVES HAVING NITROGEN MONOXIDE SYNTHASE INHIBITORY ACTIVITY Chugai Seiyaku Kabushiki Kaisha (JP) 1997-10-01 EP disclosed
US-4233431-A HEAT AND CHEMICAL RESISTANT STABILIZERS-POLYCARBONATE BAYER AKTIENGESELLSCHAFT (DE) 1980-11-11 US disclosed
US-4142035-A Polycondensates containing hydroxyquinoline end groups, their use for the preparation of polymers containing metals and metal containing polycondensates BAYER AKTIENGESELLSCHAFT (DE) 1979-02-27 US disclosed
US-4137219-A STABILIZERS BAYER AKTIENGESELLSCHAFT (DE) 1979-01-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260070915-A1 SUBSTITUTED 7H-PYRROLO[2,3-D]PYRIMIDIN-2-AMINES AS SELECTIVE CDK2/4 INHIBITORS CDK4, CDK2, CCNC CYP3A4 970/4885TSHR 1987/4885CA1 3090/4885
US-20040152742-A1 Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds MCHR2, MCHR1, NPY1R CYP3A4 3948/4885TSHR 88/4885CA1 4048/4885
US-20070173488-A1 Pyrazolothiazole Protein Kinase Modulators MAP4K2, MAP4K5, MAP4K3 CYP3A4 2211/4885TSHR 1928/4885CA1 4771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.